Design of Cytochrome P450 1B1 Inhibitors via a Scaffold-Hopping Approach
Austin C Hachey1, Alexander D Fenton1, David K Heidary1
1Department of Chemistry, University of Kentucky, 505 Rose Street, Lexington, Kentucky40506, United States.
Abstract:
Cytochrome P450 1B1 (CYP1B1) is a potential drug target in cancer research that is overexpressed in several solid tumors but is present only at low levels in healthy tissues. Its expression is associated with resistance to common chemotherapeutics, while inhibitors restore efficacy to these drugs in model systems. The majority of CYP1B1 inhibitors are derived from a limited number of scaffolds, and few have achieved outstanding selectivity against other human CYPs, which could impede clinical development. This study explores a new chemical space for CYP1B1 inhibitors using a scaffold-hopping approach and establishes 2,4-diarylthiazoles as a promising framework for further development. From a small library, compound 15 emerged as the lead, with picomolar CYP1B1 inhibition, and over 19,000-fold selectivity against its relative, CYP1A1. To investigate the activity of 15, molecular dynamics, optical spectroscopy, point mutations, and traditional structure-activity relationships were employed and revealed key interactions important for the development of CYP1B1 inhibitors.
Insights
Researchers identified novel 2,4-diarylthiazole inhibitors targeting Cytochrome P450 1B1 (CYP1B1) for cancer therapy. Compound 15 shows high selectivity and potent inhibition, offering a promising new drug development avenue.
Area of Science:
- Biochemistry
- Medicinal Chemistry
- Pharmacology
Background:
- Cytochrome P450 1B1 (CYP1B1) is upregulated in solid tumors, contributing to chemotherapy resistance.
- Existing CYP1B1 inhibitors lack sufficient selectivity, hindering clinical translation.
- Novel scaffolds are needed to overcome limitations in current CYP1B1 inhibitor development.
Purpose of the Study:
- To explore new chemical scaffolds for potent and selective CYP1B1 inhibition.
- To identify lead compounds for cancer therapy by targeting CYP1B1.
- To investigate structure-activity relationships for optimized CYP1B1 inhibitor design.
Main Methods:
- Scaffold-hopping approach to identify novel chemical entities.
- Synthesis and screening of a small library of 2,4-diarylthiazoles.
- Molecular dynamics, optical spectroscopy, and point mutations to elucidate binding interactions.
Main Results:
- Compound 15, a 2,4-diarylthiazole derivative, demonstrated picomolar inhibition of CYP1B1.
- Compound 15 exhibited over 19,000-fold selectivity against CYP1A1.
- Key molecular interactions driving CYP1B1 inhibition were identified.
Conclusions:
- 2,4-diarylthiazoles represent a promising scaffold for developing selective CYP1B1 inhibitors.
- Compound 15 serves as a valuable lead for further optimization in cancer drug discovery.
- Understanding key interactions facilitates the design of next-generation CYP1B1-targeted therapeutics.
